Przejdź do zawartości
Merck

Przejdź do

I1656

Idarubicin hydrochloride

Topoisomerase II inhibitor, solid

Synonim(y):

(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione, 4-Demethoxydaunorubicin hydrochloride, DMDR, IMI-30, Idamycin

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
10 mg
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
1080,00 zł

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C26H27NO9 · HCl
Numer CAS:
Masa cząsteczkowa:
533.95
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
260-990-7
MDL number:
Form:
solid
Quality level:

1080,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


Nazwa produktu

Idarubicin hydrochloride, solid

form

solid

Quality Level

originator

Johnson & Johnson

shipped in

wet ice

storage temp.

2-8°C

SMILES string

[H][C@@]1(C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O)O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5

InChI

1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1

InChI key

XDXDZDZNSLXDNA-TZNDIEGXSA-N

Gene Information

human ... TOP2A(7153)

Application

Idarubicin is an anthracycline antibiotic that is an anti-leukemia agent with higher DNA binding capacity and greater cytotoxicity than daunorubicin.

Biochem/physiol Actions

Topoisomerase II inhibitor

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
1335701UC211A8727
USP

USP

1335701

Idarubicin

form

solid

form

-

form

solid

form

solid

Quality Level

200

Quality Level

-

Quality Level

200

Quality Level

100

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

shipped in

wet ice

shipped in

-

shipped in

-

shipped in

-

originator

Johnson & Johnson

originator

-

originator

-

originator

-

Gene Information

human ... TOP2A(7153)

Gene Information

human ... TOP2A(7153)

Gene Information

-

Gene Information

-


Still not finding the right product?

Explore all of our products under


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Carc. 2 - Repr. 1B

Klasa składowania

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges



Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów


Produkty

DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Zobacz wszystkie artykuły

Jungwon Huh et al.
American journal of hematology, 87(10), 961-968 (2012-08-14)
Core binding factor (CBF) AML with the D816 C-KIT gene mutation demonstrate inferior treatment outcomes. However, the remaining cases without the D816 C-KIT mutation imply a requirement of more sophisticated dissection of the patients according to their prognosis. In this
Claude Gardin et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(3), 321-327 (2012-12-19)
Although standard chemotherapy remains associated with a poor outcome in older patients with acute myeloid leukemia (AML), it is unclear which patients can survive long enough to be considered as cured. This study aimed to identify factors influencing the long-term
Monica L Guzman et al.
Proceedings of the National Academy of Sciences of the United States of America, 99(25), 16220-16225 (2002-11-27)
Acute myelogenous leukemia (AML) is typically a disease of stem progenitor cell origin. Interestingly, the leukemic stem cell (LSC) shares many characteristics with normal hematopoietic stem cells (HSCs) including the ability to self-renew and a predominantly G(0) cell-cycle status. Thus



Questions

1–5 of 5 Questions  
  1. Is this soluble in DMSO, if yes then what conc.?

    1 answer
    1. This product has not been tested for solubility in DMSO. However, other sources suggest that this compound can be solubilized in DMSO at approximately 10 mg/mL. This information has not been validated.

      Helpful?

  2. What is the Department of Transportation shipping information for this product?

    1 answer
    1. Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product.

      Helpful?

  3. What is the mode of action for idarubicin?

    1 answer
    1. Idarubicin is an intercalating analog of daunorubicin that interferes with nucleic acid synthesis.  It is an anti-tumor antibiotic used in the treatment of leukemia.

      Helpful?

  4. How is idarubicin used therapeutically?

    1 answer
    1. Idarubicin is an antineoplastic drug used to treat AML (Acute Myeloid Leukemia).  In addition this compound has also been used in the treatment of breast cancer, non-Hodgkin's lymphoma, and both acute nonlymphocytic and chronic myelogenous leukemias.

      Helpful?

  5. What can be used to make a solution of Idarubicin hydrochloride, Product I1656?

    1 answer
    1. We test the solubility of idarubicin hydrochloride at 20 mg/ml of methanol.  Idarubicin hydrochloride is also slightly soluble in water (10 mg/ml water with slight heat) and slightly soluble in ethanol.

      Helpful?

Reviews

No rating value

Active Filters